These findings demonstrate a new approach for enhancing TRAIL-mediated anticancer activity in NSCLC cells via apigenin through the suppression of the Akt, NF-κB, and ERK pathways [87]. This evidence concerns the gene TNFSF10 and non-small cell lung carcinoma.